OncoMatch/Clinical Trials/NCT04077099
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Is NCT04077099 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies REGN5093 for nsclc.
Treatment: REGN5093 — This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MET alteration
Documented presence of MET alteration as described in the protocol.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: approved systemic therapy
Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks as described in the protocol
Cannot have received: radiation therapy
Has received radiation therapy or major surgery within 14 days as described in the protocol
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of California Irvine Medical Center - Bldg 56, RT81, Rm 241 · Orange, California
- Georgetown University Medical Center · Washington D.C., District of Columbia
- Moffitt Cancer Center - McKinley Drive · Tampa, Florida
- University of Kentucky, Markey Cancer Center Clinical Research Organization · Lexington, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify